<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339415</url>
  </required_header>
  <id_info>
    <org_study_id>PCC-008</org_study_id>
    <nct_id>NCT02339415</nct_id>
  </id_info>
  <brief_title>Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease</brief_title>
  <acronym>TACTICAL-HIV</acronym>
  <official_title>Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via
      edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that increased generation of activated factor X (FXa) contributes to a
      systemic elevation in pro-inflammatory cytokine levels (e.g. IL-6) among HIV positive
      patients. This occurs, in part, via FXa activation of protease activated receptor 2 (PAR-2)
      on monocytes and tissue macrophages, which perpetuates innate inflammation. We will test our
      hypothesis with an oral antagonist to FXa (edoxaban), and quantify the immunologic effects of
      PAR-2 inhibition on systemic inflammation and monocyte activation.

      The potential benefits of pharmacologic inhibition of FXa will be studied among HIV positive
      participants receiving ART with suppressed HIV viral load and a D-dimer &gt;100 ng/mL. The study
      design is a cross-over placebo controlled randomized trial of edoxaban 30mg daily versus
      matched placebo (n=40 total participants). After screening and baseline visits, participants
      will be randomized to the sequence of drug administration (i.e., edoxaban vs. placebo). After
      randomization, participants will start study medication #1 and follow-up for visits at months
      1, 2, 3 and 4. They will then stop study medication for 3 months, return for visits at months
      7 and 8 (analogous to screening and baseline, respectively), then start study medication #2
      and follow-up for visits at months 9, 10, 11, and 12.

      The treatment effect (i.e., changes from pre-treatment levels) over 4 months will be assessed
      in measures of inflammation, immune activation, and coagulation. For comparisons with
      placebo, each participant will then serve as his or her own control in this cross-over
      design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months.</measure>
    <time_frame>Through study completion, an average of 4 months on each treatment.</time_frame>
    <description>Difference between treatment and control ln-transformed IL-6 plasma levels in change from pre-treatment to on-treatment values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in D-Dimer Levels From Baseline to 4 Months</measure>
    <time_frame>Through study completion, an average of 4 months on each treatment.</time_frame>
    <description>Difference between treatment and control ln-transformed D-Dimer levels in change from pre-treatment to on-treatment values</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety (Bleeding Events)</measure>
    <time_frame>4 months while on Edoxaban or Placebo</time_frame>
    <description>Number of bleeding events on Edoxaban or Placebo.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Inflammation</condition>
  <condition>Coagulation</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edoxaban 30mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban 30mg daily</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  HIV infection (verified by previous positive antibody or detectable HIV RNA level)

          -  Age ≥18 years

          -  Receiving continuous ART for ≥2 years (regimen changes &gt;3 months prior to enrollment
             are acceptable)

          -  HIV RNA level ≤200 copies/mL for ≥1 year (1 measure ≥200 allowed if also &lt;500 and
             preceded and followed by one or more values ≤200 copies/mL)

          -  D-dimer level ≥100 mg/L (or ng/mL) at screening (or within the prior month)

          -  Estimated creatinine clearance ≥50 mL/min

          -  Body weight ≥60kg

          -  Do not anticipate starting (or stopping) statin or aspirin therapy during the study

          -  For women of child bearing potential, agrees to use a reliable form of birth control

        Exclusion Criteria

          -  Pregnancy or breast feeding

          -  A contra-indication to taking edoxaban

          -  A clinical indication for anticoagulation therapy (e.g., atrial fibrillation or Deep
             Vein Thrombosis/PE)

          -  Treatment with anti-platelet, anti-coagulation, or immune-modulatory drugs currently
             or within the past 6 months; prior self-limited treatment with aspirin (i.e., not
             daily use) is not itself an exclusion.

          -  Grade ≥1 hematology lab abnormality for INR (&gt;1.1 x ULN), hemoglobin (&lt;10.0 g/L),
             platelets (&lt;100,000 cells/μL), and WBC (2,500 cells/mm3)

          -  Grade ≥2 lab abnormality for chemistries (BMP) or liver panel

          -  Alcohol or illicit drug abuse/dependency within the prior year

          -  History of prior myocardial infarction or unstable atherosclerotic disease

          -  History of prior stroke or transient ischemic attack (TIA)

          -  History of active gastrointestinal ulcer or bleeding disorder within the prior year

          -  Intent to have surgery during the study period (12 months)

          -  Hepatitis C treatments (e.g., interferon, ribavirin, protease inhibitors) within the
             past 6 months

          -  Cirrhosis or hepatic impairment (e.g., Child-Pugh class B or C).

          -  Seizure disorder

          -  Previous/current CNS space occupying lesion (e.g., Toxoplasmosis, mTB) with persistent
             abnormalities on CNS imaging after completion of treatment.

          -  Surgical or invasive procedure anticipated during study period.

          -  Invasive cancer in the prior year or receiving cancer treatment (not including
             carcinoma-in-situ or basal cell cancer of the skin)

          -  Rheumatologic or inflammatory disease, systemic in nature (e.g., systemic lupus
             erythematosus, rheumatoid arthritis, vasculitis, sarcoidosis, Crohn's disease)

          -  Assessment by the clinical investigator that enrollment into the study could entail
             excess risk to the participant, beyond what is intended or expected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Baker, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin Healthcare Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <results_first_submitted>February 17, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hennepin Healthcare Research Institute</investigator_affiliation>
    <investigator_full_name>Jason Baker</investigator_full_name>
    <investigator_title>Protocol Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02339415/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo First Then Edoxaban</title>
          <description>Participants receive placebo during first period, then Edoxaban (30mg daily) in second period after washout.</description>
        </group>
        <group group_id="P2">
          <title>Edoxaban First Then Placebo</title>
          <description>Participants receive Edoxaban (30mg daily) in first period, then placebo during second period after washout.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo First Then Edoxaban</title>
          <description>Participants receive placebo during first period, then Edoxaban (30mg daily) in second period after washout.</description>
        </group>
        <group group_id="B2">
          <title>Edoxaban First Then Placebo</title>
          <description>Participants receive Edoxaban (30mg daily) in first period, then placebo during second period after washout.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="8"/>
                    <measurement group_id="B2" value="47" spread="10"/>
                    <measurement group_id="B3" value="49" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (Non-Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.4" spread="17.3"/>
                    <measurement group_id="B2" value="126.1" spread="13.0"/>
                    <measurement group_id="B3" value="124.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.4" spread="11.0"/>
                    <measurement group_id="B2" value="78.9" spread="10.4"/>
                    <measurement group_id="B3" value="80.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin-6 (IL-6)</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.695" lower_limit="0.520" upper_limit="1.080"/>
                    <measurement group_id="B2" value="0.465" lower_limit="0.380" upper_limit="0.980"/>
                    <measurement group_id="B3" value="0.575" lower_limit="0.395" upper_limit="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>D-dimer</title>
          <units>μg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.18" lower_limit="0.11" upper_limit="0.24"/>
                    <measurement group_id="B2" value="0.18" lower_limit="0.13" upper_limit="0.34"/>
                    <measurement group_id="B3" value="0.18" lower_limit="0.12" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months.</title>
        <description>Difference between treatment and control ln-transformed IL-6 plasma levels in change from pre-treatment to on-treatment values</description>
        <time_frame>Through study completion, an average of 4 months on each treatment.</time_frame>
        <population>44 participants were randomized to each arm, of those, 41 went on to receive placebo and have follow up data, 40 received study drug (Edoxaban) and had follow up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban</title>
            <description>30mg of Edoxaban</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months.</title>
          <description>Difference between treatment and control ln-transformed IL-6 plasma levels in change from pre-treatment to on-treatment values</description>
          <population>44 participants were randomized to each arm, of those, 41 went on to receive placebo and have follow up data, 40 received study drug (Edoxaban) and had follow up data.</population>
          <units>ln-pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.39"/>
                    <measurement group_id="O2" value="0.09" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>included predictors: treatment, assigned treatment sequence and pre-treatment biomarker level.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>because biomarkers were analyzed on natural log scale, the estimated parameter is the log-transformed mean percent difference in treatment effect on Edoxaban vs. Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-Dimer Levels From Baseline to 4 Months</title>
        <description>Difference between treatment and control ln-transformed D-Dimer levels in change from pre-treatment to on-treatment values</description>
        <time_frame>Through study completion, an average of 4 months on each treatment.</time_frame>
        <population>44 participants were randomized to each arm, of those, 41 went on to receive placebo and have follow up data, 40 received study drug (Edoxaban) and had follow up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban</title>
            <description>30mg of Edoxaban</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-Dimer Levels From Baseline to 4 Months</title>
          <description>Difference between treatment and control ln-transformed D-Dimer levels in change from pre-treatment to on-treatment values</description>
          <population>44 participants were randomized to each arm, of those, 41 went on to receive placebo and have follow up data, 40 received study drug (Edoxaban) and had follow up data.</population>
          <units>ln-μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.77"/>
                    <measurement group_id="O2" value="-0.66" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>included predictors: treatment, assigned treatment sequence and pre-treatment biomarker level.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>because biomarkers were analyzed on natural log scale, the estimated parameter is the log-transformed mean percent difference in treatment effect on Edoxaban vs. Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety (Bleeding Events)</title>
        <description>Number of bleeding events on Edoxaban or Placebo.</description>
        <time_frame>4 months while on Edoxaban or Placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Receiving Placebo</title>
            <description>Administered matched placebo</description>
          </group>
          <group group_id="O2">
            <title>Receiving Edoxaban</title>
            <description>Administered 30mg of Edoxaban</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (Bleeding Events)</title>
          <description>Number of bleeding events on Edoxaban or Placebo.</description>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding gums</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloody stool</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laceration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matched placebo</description>
        </group>
        <group group_id="E2">
          <title>Edoxaban</title>
          <description>30mg of Edoxaban</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anemia, unspecified iron deficiency anemia type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bleeding from a minor dog bite (puppy) with unusual bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bleeding of minor cuts/slow healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>bleeding gums</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood in stool</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Acute macular neuroretinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting and Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>exhaustion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Laceration secondary to syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 AST due to HCV seroconversion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Grade 4 ALT due to HCV seroconversion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>cut head, slipped on ice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hit by softball, bleeding from eye laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Laceration secondary to coffee pot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Laceration secondary to meat slicer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured L5 disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Osteoporosis diagnosis via DEXA on routine clinical screening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Severe back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Baker</name_or_title>
      <organization>Hennepin Healthcare Research Institute</organization>
      <phone>612-873-2705</phone>
      <email>baker@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

